Table 1

Clinical data in patients with RA suggested to be representative for the entire RA population

All (n=287)Women (n=235)Men (n=52)
Except where otherwise indicated, values are mean (SD).
*The number varies from 287 in all patients or from 235 in women patients owing to missing values; †the mean ESR and CRP values are based on two measurements performed two years apart; ‡oestradiol, bisphosphonates or calcitonin; BMI=body mass index; RF=rheumatoid factor positive; VAS=visual analogue scale; HAQ=Health Assessment Questionnaire, mHAQ=modified Health Assessment Questionnaire; ESR=erythrocyte sedimentation rate; CRP=C reactive protein.
Demographic variables:
    Age (years)57.6 (11.0)56.8 (11.0)61.5 (10.2)
    Body weight (kg)68.4 (12.9)65.8 (11.5)80.2 (12.4)
    Body height (cm)167.8 (7.8)165.5 (5.9)178.2 (6.8)
    BMI (kg/m2)24.2 (4.1)24.0 (4.2)25.2 (3.2)
    Menopause163 (69.4%)
    Menopause age (years)48.7 (4.8)
    Current smoker (n=282)*100 (35.5%)80 (34.6%)20 (39.2%)
Disease variables:
    Disease duration (years)15.4 (9.4)15.5 (9.5)14.7 (8.6)
    RF positive (n=269)*134 (49.8%)109 (50.0%)25 (49.0%)
    Global assessment score (VAS 0–100 mm) (n=259)*23.7 (18.7)23.7 (18.4)23.7 (20.0)
    HAQ (range 0–3)0.99 (0.67)1.01 (0.66)0.91 (0.70)
    mHAQ score (range 1–4)1.60 (0.51)1.61 (0.52)1.55 (0.48)
    Mean ESR† (n=285)*20.8 (15.9)20.7 (15.5)21.4 (17.7)
    Mean CRP† (n=238)* (mg/l)15.8 (13.0)15.3 (12.0)18.0 (16.3)
Treatment variables:
    Current prednisolone use (n=287)125 (44%)102 (44%)23 (44%)
    Ever prednisolone use (n=287)189 (66%)157 (667)32 (62%)
    Duration of prednisolone use among current users (months) (n=122)Median 78 (range 1–500)Median 84 (range 1–480)Median 60 (range 18–500)
    Cumulative prednisolone dose in past 12 months (g) (n=129)2.1 (1.4)2.1 (1.4)2.1 (1.5)
    Current use of oestradiol (n=230)*88 (38%)
    Current use of any antiresorptive osteoporosis treatment‡ (n=283)*107 (38%)104 (45%)3 (6%)